| Title | Comparison of inflammatory markers in psoriatic patients before and after treatment with etanercept | ||
| Authors | A. Kanelleas1, C. Liapi2, Α.Ι. Liakou1, A. Katoulis1, P.N. Giannoukos, T. Economopoulos3 and N.G. Stavrianeas1
1. Second Department of Dermatology and Venereology, Attikon University General Hospital, School of Medicine, National and Kapodistrian University of Athens, Greece 2. Department of Pharmacology, Medical School, National and Kapodistrian University of Athens, Greece 3. Second Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Attikon University General Hospital, Athens, Greece |
||
| Citation | Kanelleas, A., Liapi, C., Liakou, A.I., Katoulis, A., Giannoukos, P.N. et al.: Comparison of inflammatory markers in psoriatic patients before and after treatment with etanercept, Epitheorese Klin. Farmakol. Farmakokinet. 24(2): 149-160 (2010) | ||
| Publication Date | 2010 | ||
| Full Text Language | English | ||
| Order – Buy | Ηλεκτρονική Μορφή: pdf (10 €) – Digital Type: pdf (10 €)
pharmakonpress[at]pharmakonpress[.]gr |
||
| Keywords | Psoriasis, etanercept, inflammation, biological treatment. | ||
| Other Terms | Review article | ||
| Summary | Psoriasis is a chronic, systemic, inflammatory disease affecting mainly the skin and the joints. It is an immune cell-mediated disease in which T-lymphocyte activation and a subsequent inflammatory response are of great importance in its pathogenesis. We measured an array of inflammatory markers in psoriatic patients eligible for biological treatment. The comparison of this group at baseline and after twelve weeks of Etanercept treatment revealed a statistically important reduction in all markers as well as PASI score. This suggests that there might be an association between clinical improvement and reduced inflammatory burden. | ||
| References | 1. Griffiths C.E.M., Barker J.N.W.N.: Pathogenesis and clinical features of psoriasis. Lancet 370: 263-271 (2007)
2. Gelfand J.M., Neimann A.L., Shin D.B. et al.: Risk of myocardial infarction in patients with psoriasis. JAMA 296: 1735-1741 (2006) 3. Lowes M.A., Bowcock A.M., Krueger J.G.: Pathogenesis and therapy of psoriasis. Nature 445: 866-873 (2007) 4. Rashmi R., Rao K.S.J., Basavaraj K.H.: A comprehensive review of biomarkers in psoriasis. Clin. Exper. Dermatol. 34: 658-663 (2009) 5. Rocha-Pereira P., Santos-Silva A., Rebelo I. et al.: The inflammatory response in mild and in severe psoriasis. Br. J. Dermatol. 150: 917-928 (2004) 6. Strober B., Teller C., Yamauchi P., et al.: Effects of Etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br. J. Dermatol. 159: 322-330 (2008) 7. Pathirana D., Ormerod A.D., Saiag P., et al.: European S3-Guidelines on the systemic treatment of psoriasis vulgaris. J. Eur. Acad. Dermatol. Venereol. 23(suppl 2): 34-38 (2009) |
||
| Relative Papers | |||
Online ISSN 1011-6575
Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
- Chemical Abstracts
- Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Articles published in this Journal are Indexed or Abstracted in: • Chemical Abstracts • Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Συντακτικη Επιτροπή-Editorial Board
| ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ 2010 – ANNUAL SUBSCRIPTION 2010 | |
| Γλώσσα Πλήρους Κειμένου – Full Text Language | Αγγλικά – English |
| Παραγγελία – Αγορά – Order – Buy | Ηλεκτρονική Μορφή: pdf (70 €) – Digital Type: pdf (70 €)
pharmakonpress[at]pharmakonpress[.]gr |
| Έντυπη Μορφή (70 € + έξοδα αποστολής) – Printed Type (70 € + shipping)
pharmakonpress[at]pharmakonpress[.]gr |
|